Item 8.01 Other Events.

On December 1, 2022, Anavex Life Sciences Corp., a Nevada corporation (the "Company") issued a press release (the "Press Release") providing top line data from its Phase 2b/3 double-blind, placebo-controlled trial of ANAVEX®2-73 in Alzheimer's disease. The trial met its primary and key secondary endpoints with statistically significant results. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






  (d)  Exhibits




EXHIBIT NO.     DESCRIPTION         LOCATION
99.1              Press Release       Filed herewith

© Edgar Online, source Glimpses